Intercell Signs Exclusive Agreement for Marketing and Distribution of its Japanese Encephalitis Vaccine in Japan and Korea
Under the terms of this agreement, Novartis receives the exclusive marketing and distribution rights in Japan and Korea and obtains a distribution margin on all product sales in these territories. Additional financial details were not disclosed.
"Japanese Encephalitis is endemic to Japan and Korea and poses a significant risk, particularly to children", said Gerd Zettlmeissl, Chief Executive Officer of Intercell. "It was a priority for Intercell to identify a very strong marketing partner for these markets, where the disease is a major public health threat and we are convinced that Novartis – with its global reach – is ideally suited."
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.